NRARP target sequences (cDNA)	
SEQ ID NO. 1	CACCAGGACATCGTGCTCT
SEQ ID NO. 2	ACATCGTGCTCTATCTCAT
SEQ ID NO. 3	AGGACATCGTGCTCTATCT
SEQ ID NO. 4	GACATCGTGCTCTATCTCA
SEQ ID NO. 5	TGCTCTATCTCATCACCAA
SEQ ID NO. 6	CCAGGACATCGTGCTCTAT
SEQ ID NO. 7	ATCGTGCTCTATCTCATCA
SEQ ID NO. 8	GTGCTCTATCTCATCACCA
SEQ ID NO. 9	ACCAGGACATCGTGCTCTA

FIGURE 1

NRARP siRNAs	Sense strand 5'->3'	Antisense strand 5' ->3'
SEQ ID NO. 10	CACCAGGACAUCGUGCUCU	AGAGCACGAUGUCCUGGUG
SEQ ID NO. 11	ACAUCGUGCUCUAUCUCAU	AUGAGAUAGAGCACGAUGU
SEQ ID NO. 12	AGGACAUCGUGCUCUAUCU	AGAUAGAGCACGAUGUCCU
SEQ ID NO. 13	GACAUCGUGCUCUAUCUCA	UGAGAUAGAGCACGAUGUC
SEQ ID NO. 14	UGCUCUAUCUCAUCACCAA	UUGGUGAUGAGAUAGAGCA
SEQ ID NO. 15	CCAGGACAUCGUGCUCUAU	AUAGAGCACGAUGUCCUGG
SEQ ID NO. 16	AUCGUGCUCUAUCUCAUCA	UGAUGAGAUAGAGCACGAU
SEQ ID NO. 17	GUGCUCUAUCUCAUCACCA	UGGUGAUGAGAUAGAGCAC
SEQ ID NO. 18	ACCAGGACAUCGUGCUCUA	UAGAGCACGAUGUCCUGGU

FIGURE 2

Modified NRARP siRNAs	Sense strand 5'-3'	Antisense strand 5'-3'	Chemical modification
SEQ ID NO. 19	cAc*cA*GGAcAucGuGCu*Cu	A*GAGCACGAUGUCCuGgug (SEQ ID NO. 20)	PS+2'OMe (S) / 2'OMe+PS (AS)
SEQ ID NO. 21	cAc*cA*GGAcAucGuGCu*Cu	A*GAGCACGAUGUCCugGug (SEQ ID NO. 22)	PS+2'OMe (S) / 2'OMe+4'S+PS (AS)
SEQ ID NO. 23	cAc*cA*GGAcAucGuGCu*Cu	A*GAGCACGAUGUCCpUGGpUG (SEQ ID NO. 24)	PS+2'OMe (S) / 5pU+PS (AS)
SEQ ID NO. 25	cAc*cA*GGAcAucGuGCu*Cu	AGAGCACGAUGUCCuGGuG (SEQ ID NO. 26)	PS+2'OMe (S) / 2'O Me+2'F (AS)
SEQ ID NO. 27	cAc*cA*GGAcAucGuGCu*Cu	AGAGCACGAUGUCCuGguG (SEQ ID NO. 28)	PS+2'OMe (S) / 2'OMe+2'F (AS)
SEQ ID NO. 29	CAc*cA*GGAcAucGuGCu*Cu	AGAGCACGAUGUCCuGguG (SEQ ID NO. 30)	PS+2'OMe (S) / 2'OMe+2'F (AS)
SEQ ID NO. 31	cAccAGGAcAucGuGcucu	AGAGcaCGAuGUCCuGGuG (SEQ ID NO. 32)	2'OMe (S) / 2'OMe+2'F (AS)
SEQ ID NO. 33	CAccAGGAcAucGuGcucu	aGAGcaCGAuGUCCuGGuG (SEQ ID NO. 34)	2'OMe+2'F (S) / 2'OMe (AS)
SEQ ID NO. 35	CACCAGGACAUCGUGCUCUdTdT	AGAGCACGAUGUCCUGGUGdTdT (SEQ ID NO. 36)	2'H (S) / 2'H (AS)
SEQ ID NO. 37	caCcAgGaCaUcGuGcUcU	AGaGcAcGaUgUcCuGgUg (SEQ ID NO. 38)	2'OMe+2'F (S) / 2'OMe+2'F (AS)
SEQ ID NO. 39	cAccAGGAcAucGuGcucu	AGAGcACGAUGUCCUGGUG (SEQ ID NO. 40)	2'OMe (S) / 2'OMe (AS)
SEQ ID NO. 41	ACA*UC*GUGCUCUAuCUC*AU	AUGAGAUAGAGCACgAuGu (SEQ ID NO. 42)	PS+2'OMe (S) / 2'OMe (AS)
SEQ ID NO. 43	AcA*UC*GuGCUCuAuCUc*AU	AUGAGAUAGAGCACgAuGu (SEQ ID NO. 44)	PS+2'OMe (S) / 2'OMe (AS)
SEQ ID NO. 45	AcA*UC*GuGCUCuAuCUc*AU	AUGAGAUAGAGCACGApUGpU (SEQ ID NO. 46)	PS+2'OMe (S) / 5pU (AS)
SEQ ID NO. 47	AcA*UC*GuGCUCuAuCUc*AU	A*UGAGAUAGAGCACGAuGu (SEQ ID NO. 48)	PS+2'OMe (S) / 4'S (AS)
SEQ ID NO. 49	AcA*UC*GuGCUCuAuCUc*AU	AUGAGAUAGAGCACGAugu (SEQ ID NO. 50)	PS+2'OMe (S) / 4'S+2'OMe (AS)
SEQ ID NO. 51	AcA*UC*GuGCUCuAuCUc*AU	AuGAGAUAGAGCACGAugu (SEQ ID NO. 52)	PS+2'OMe (S) / 4'S+2'OMe (AS)
SEQ ID NO. 53	AcA*UC*GuGCUCuAuCUc*AU	A*UGAGAUAGAGCACGApUGpU (SEQ ID NO. 54)	PS+2'OMe (S) / 5pU(AS)
SEQ ID NO. 55	AcA*uc*GuGCucuAucucA*U	A*UGAGAUAGAGCACGAuGu (SEQ ID NO. 56)	PS+2'OMe(S) / PS+5mU(AS)
SEQ ID NO. 57	AcAucGuGcucuAucucAu	AuGAGAuAGAGCACGAuGu (SEQ ID NO. 58)	2'F+2'OMe (S) / 2'OMe (AS)

SEQ ID NO. 59	acAucGuGcucuAucucAu	AuGAGAuAGAGCACGAuGu (SEQ ID NO. 60)	2'OMe (S) / 2'F+2'OMe (AS)
SEQ ID NO. 61	ACAUCGUGCUCUAUCUCAUdTdT	AUGAGAUAGAGCACGAUGUdTdT (SEQ ID NO. 62)	dT(2'H) (S) / dT(2'H) (AS)
SEQ ID NO. 63	AcAucGuGcucuAucucAu	AUGAGAuAGAGcACGAUGU (SEQ ID NO. 64)	2'OMe (S) / 2'OMe (AS)
SEQ ID NO. 65	acAuCgUgCuCuAuCuCaU	AUgAgAuAgAgCACgAuGu (SEQ ID NO. 66)	2'OMe+2'F (S) / 2'OMe+2'F (AS)

FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18



Nb master juctions
T/C ratio (% front No DNA)
No DNA
No electrop.
siRNA KDR
SEQ ID NO. 37
Tot.meshes area
EBM wo supplements (6h)
EBM + 10% serum + VEGF (5h)
EBM + 10% serum + VEGF (24h)
Nb meshes

FIGURE 19




FIGURE 19 (CONT.)



EBM wo supplements_6h
EBM + 10%FCS + VEGF_6h
EBM + 10%FCS + VEGF_24h
No electroporation
Control of electroporation
1µM siRNA-KDR
1µM SEQ ID NO. 37

FIGURE 20




FIGURE 21




FIGURE 22




FIGURE 23




FIGURE 24



EBM complete + VEGF 100 ng/ml_24h
No electropor.
Control
siRNA KDR
SEQ ID NO. 37
only EBM_24h (no migrating cells)

FIGURE 25




FIGURE 26




FIGURE 27



EBM complete + VEGF 100 ng/ml
18 hours
Time 0 h
No electrop
CONTROL electrop
siRNA KDR
SEQ ID NO. 37
only EBM
18 hours
Time 0 h
No electrop
CONTROL electrop
siRNA KDR
SEQ ID NO. 37

FIGURE 28



W/O suppl
Complete
NRARP mRNA
(% over CONTROL electrop.)
140
120
100
80
60
40
20
0
CONTROL
electroporation
siRNA KDR
SEQ ID NO. 37

FIGURE 29